Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. (2021)
Attributed to:
Role of heparin binding growth factors in O.viverrini induced Cholangiocarcinoma (O-CCA) development, progression and angiogenesis
funded by
Newton Fund
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/ph14010051
PubMed Identifier: 33440754
Publication URI: http://europepmc.org/abstract/MED/33440754
Type: Journal Article/Review
Volume: 14
Parent Publication: Pharmaceuticals (Basel, Switzerland)
Issue: 1
ISSN: 1424-8247